Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 50090-7444

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-7444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C:\users\ra\desktop\1.jpg (5a5eca60 Figure 01)

This line graph compares the percentage of patients achieving systolic blood pressure (SBP) less than 140 mmHg across different baseline SBP levels. It includes four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo, plotting percentage against baseline SBP from 140 to 180 mmHg.*

FDA Label Image

C:\users\ra\desktop\2.jpg (5a5eca60 Figure 02)

A line graph showing the percentage of diastolic blood pressure (DBP) below 90 mmHg in relation to baseline DBP values ranging from 90 to 110 mmHg. The graph compares four groups: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The Valsartan-HCTZ combination consistently shows the highest percentage of DBP below 90 mmHg across the baseline range.*

FDA Label Image

C:\users\ra\desktop\3.jpg (5a5eca60 Figure 03)

A line graph comparing the percentage of subjects achieving systolic blood pressure (SBP) below 130 mmHg against baseline SBP values ranging from 140 to 180 mmHg. The chart includes data lines for Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo, illustrating differences in blood pressure control among these treatments.*

FDA Label Image

C:\users\ra\desktop\4.jpg (5a5eca60 Figure 04)

A line graph depicting the percentage of patients achieving diastolic blood pressure (DBP) below 80 mmHg relative to baseline DBP values. The graph compares four groups: valsartan-HCTZ 320/25 mg, valsartan 320 mg, hydrochlorothiazide 25 mg, and placebo, each represented by distinct markers. The x-axis shows baseline DBP (mmHg) from 90 to 110, and the y-axis shows percentage with DBP <80 mmHg from 0 to 100%.*

FDA Label Image

C:\users\ra\desktop\5.jpg (5a5eca60 Figure 05)

Chemical structure of valsartan, one of the active ingredients in the combination drug valsartan and hydrochlorothiazide. The diagram shows the molecular layout including rings and functional groups characteristic of valsartan.*

FDA Label Image

C:\users\ra\desktop\6.jpg (5a5eca60 Figure 06)

Chemical structure of valsartan and hydrochlorothiazide, illustrating the molecular framework of the active ingredients in the film-coated tablet formulation from A-S Medication Solutions.*

FDA Label Image

Label Image (Lbl500907444)

Label for VALSARTAN AND HYDROCHLOROTHIAZIDE film-coated tablets, oral route, 160 mg/25 mg strength. The label shows a lot number, storage instructions (store at 60 to 77 degrees F, protect from moisture), and a package size of 90 tablets. Distributed by A-S Medication Solutions, Libertyville, IL 60048, with NDC 50090-7444-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.